NASDAQ:GERN - Geron Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$4.11 +0.48 (+13.22 %)
(As of 05/22/2018 01:36 PM ET)
Previous Close$3.66
Today's Range$3.66 - $4.15
52-Week Range$1.74 - $6.68
Volume176,994 shs
Average Volume3.42 million shs
Market Capitalization$610.97 million
P/E Ratio-23.03
Dividend YieldN/A
Beta2.31

About Geron (NASDAQ:GERN)

Geron logoGeron Corporation operates as a biopharmaceutical company. The company supports the clinical stage development of imetelstat, a telomerase inhibitor for the treatment of hematologic myeloid malignancies. It has collaboration and license agreement with Janssen Biotech, Inc. to develop and commercialize imetelstat worldwide for indications in oncology, including hematologic myeloid malignancies and other human therapeutic uses. The company was founded in 1990 and is based in Menlo Park, California.

Receive GERN News and Ratings via Email

Sign-up to receive the latest news and ratings for GERN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:GERN
CUSIP37416310
Phone650-473-7700

Debt

Debt-to-Equity RatioN/A
Current Ratio20.80
Quick Ratio20.80

Price-To-Earnings

Trailing P/E Ratio-23.03
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$1.07 million
Price / Sales664.82
Cash FlowN/A
Price / CashN/A
Book Value$0.65 per share
Price / Book6.32

Profitability

EPS (Most Recent Fiscal Year)($0.18)
Net Income$-27,910,000.00
Net Margins-3,300.12%
Return on Equity-26.20%
Return on Assets-24.58%

Miscellaneous

Employees18
Outstanding Shares173,080,000

Geron (NASDAQ:GERN) Frequently Asked Questions

What is Geron's stock symbol?

Geron trades on the NASDAQ under the ticker symbol "GERN."

How were Geron's earnings last quarter?

Geron Co. (NASDAQ:GERN) posted its earnings results on Thursday, May, 10th. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.05) by $0.01. The biopharmaceutical company earned $0.32 million during the quarter. Geron had a negative net margin of 3,300.12% and a negative return on equity of 26.20%. During the same period in the previous year, the firm earned ($0.05) earnings per share. View Geron's Earnings History.

When is Geron's next earnings date?

Geron is scheduled to release their next quarterly earnings announcement on Wednesday, August, 8th 2018. View Earnings Estimates for Geron.

What price target have analysts set for GERN?

4 Wall Street analysts have issued 12 month price objectives for Geron's stock. Their forecasts range from $4.00 to $7.00. On average, they expect Geron's share price to reach $5.50 in the next year. View Analyst Ratings for Geron.

Are investors shorting Geron?

Geron saw a increase in short interest in April. As of April 30th, there was short interest totalling 40,050,674 shares, an increase of 14.5% from the April 13th total of 34,979,045 shares. Based on an average daily trading volume, of 5,308,605 shares, the days-to-cover ratio is presently 7.5 days. Approximately 25.1% of the company's stock are sold short.

Who are some of Geron's key competitors?

Who are Geron's key executives?

Geron's management team includes the folowing people:
  • Dr. John A. Scarlett, CEO, Pres & Director (Age 67)
  • Ms. Olivia Kyusuk Bloom, Exec. VP of Fin., CFO & Treasurer (Age 49)
  • Dr. Andrew J. Grethlein, Exec. VP of Devel. & Technical Operations (Age 54)
  • Mr. Stephen N. Rosenfield, Exec. VP, Gen. Counsel & Corp. Sec. (Age 68)
  • Ms. Melissa A. Kelly Behrs, Exec. VP of Bus. Devel. and Portfolio & Alliance Management (Age 54)

Has Geron been receiving favorable news coverage?

Headlines about GERN stock have been trending somewhat positive on Tuesday, Accern reports. Accern identifies positive and negative news coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Geron earned a daily sentiment score of 0.15 on Accern's scale. They also gave press coverage about the biopharmaceutical company an impact score of 47.36 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next several days.

Who are Geron's major shareholders?

Geron's stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (7.37%), Northern Trust Corp (1.12%), Swiss National Bank (0.18%), Arnhold LLC (0.10%), A.R.T. Advisors LLC (0.09%) and NJ State Employees Deferred Compensation Plan (0.09%). View Institutional Ownership Trends for Geron.

Which major investors are selling Geron stock?

GERN stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., NJ State Employees Deferred Compensation Plan, Northern Trust Corp, MetLife Investment Advisors LLC and Teacher Retirement System of Texas. View Insider Buying and Selling for Geron.

Which major investors are buying Geron stock?

GERN stock was acquired by a variety of institutional investors in the last quarter, including Arnhold LLC, M Holdings Securities Inc., OMERS ADMINISTRATION Corp, UBS Group AG, A.R.T. Advisors LLC, Bayesian Capital Management LP, Element Capital Management LLC and Swiss National Bank. View Insider Buying and Selling for Geron.

How do I buy shares of Geron?

Shares of GERN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Geron's stock price today?

One share of GERN stock can currently be purchased for approximately $4.03.

How big of a company is Geron?

Geron has a market capitalization of $610.97 million and generates $1.07 million in revenue each year. The biopharmaceutical company earns $-27,910,000.00 in net income (profit) each year or ($0.18) on an earnings per share basis. Geron employs 18 workers across the globe.

How can I contact Geron?

Geron's mailing address is 149 COMMONWEALTH DRIVE SUITE 2070, MENLO PARK CA, 94025. The biopharmaceutical company can be reached via phone at 650-473-7700 or via email at [email protected]


MarketBeat Community Rating for Geron (GERN)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  245 (Vote Outperform)
Underperform Votes:  195 (Vote Underperform)
Total Votes:  440
MarketBeat's community ratings are surveys of what our community members think about Geron and other stocks. Vote "Outperform" if you believe GERN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GERN will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Geron (NASDAQ:GERN) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
4 Wall Street analysts have issued ratings and price targets for Geron in the last 12 months. Their average twelve-month price target is $5.50, suggesting that the stock has a possible upside of 33.82%. The high price target for GERN is $7.00 and the low price target for GERN is $4.00. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.502.502.502.50
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $5.50$5.50$4.1667$4.1667
Price Target Upside: 33.82% upside29.41% upside96.54% upside96.54% upside

Geron (NASDAQ:GERN) Consensus Price Target History

Price Target History for Geron (NASDAQ:GERN)

Geron (NASDAQ:GERN) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/19/2018Piper Jaffray CompaniesReiterated RatingBuy$7.00HighView Rating Details
3/18/2018Stifel NicolausBoost Price TargetHold ➝ Hold$2.50 ➝ $4.00HighView Rating Details
11/3/2017Needham & Company LLCReiterated RatingHoldN/AView Rating Details
7/4/2017FBR & CoReiterated RatingBuyMediumView Rating Details
9/20/2016BTIG ResearchReiterated RatingNeutralN/AView Rating Details
(Data available from 5/22/2016 forward)

Earnings

Geron (NASDAQ:GERN) Earnings History and Estimates Chart

Earnings by Quarter for Geron (NASDAQ:GERN)

Geron (NASDAQ GERN) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/8/2018        
5/10/2018Q1 18($0.05)($0.04)$0.32 millionViewN/AView Earnings Details
3/16/2018Q4 2017($0.04)($0.05)$0.41 million$0.19 millionViewListenView Earnings Details
11/1/2017Q3 2017($0.05)($0.04)$0.40 million$0.16 millionViewN/AView Earnings Details
8/9/2017Q2 2017($0.05)($0.04)$0.38 million$0.17 millionViewN/AView Earnings Details
5/9/2017Q1 2017($0.05)($0.05)$0.27 million$0.54 millionViewN/AView Earnings Details
3/1/2017Q416($0.06)($0.05)$0.18 million$0.09 millionViewListenView Earnings Details
11/3/2016Q316($0.06)($0.02)$0.22 million$5.10 millionViewListenView Earnings Details
8/3/2016Q216($0.07)($0.05)$0.38 million$0.21 millionViewListenView Earnings Details
5/5/2016Q116($0.06)($0.06)$0.26 million$0.74 millionViewListenView Earnings Details
2/25/2016Q415($0.05)($0.05)$0.32 million$0.22 millionViewListenView Earnings Details
11/5/2015Q315$0.11$0.17$17.87 million$35.40 millionViewListenView Earnings Details
8/5/2015Q2 15($0.06)($0.05)$0.40 million$0.25 millionViewN/AView Earnings Details
4/30/2015Q1($0.06)($0.06)$0.32 million$0.54 millionViewN/AView Earnings Details
3/3/2015Q4$0.17($0.06)$35.35 million$0.18 millionViewListenView Earnings Details
11/5/2014Q314($0.06)($0.06)$0.28 million$0.16 millionViewN/AView Earnings Details
8/11/2014Q214($0.06)($0.06)$0.22 million$0.34 millionViewListenView Earnings Details
5/1/2014Q114($0.06)($0.06)$0.35 million$0.47 millionViewListenView Earnings Details
3/27/2014($0.06)($0.07)ViewN/AView Earnings Details
3/17/2014Q413($0.07)($0.07)$0.35 million$0.23 millionViewListenView Earnings Details
11/7/2013Q313($0.06)($0.06)$0.49 million$0.18 millionViewListenView Earnings Details
8/8/2013Q2 2013($0.07)($0.07)$0.50 million$0.11 millionViewListenView Earnings Details
4/25/2013Q1 2013($0.08)($0.09)$0.71 million$0.77 millionViewListenView Earnings Details
3/12/2013Q4 2012($0.14)($0.12)$0.50 million$0.69 millionViewListenView Earnings Details
10/30/2012Q312($0.14)($0.13)$0.38 million$0.6360 millionViewN/AView Earnings Details
7/31/2012($0.15)($0.14)ViewN/AView Earnings Details
5/2/2012($0.18)($0.15)ViewN/AView Earnings Details
3/7/2012Q4 2011($0.20)($0.22)ViewN/AView Earnings Details
11/3/2011($0.18)($0.16)ViewN/AView Earnings Details
7/28/2011($0.18)($0.17)ViewN/AView Earnings Details
4/27/2011($0.19)($0.20)ViewN/AView Earnings Details
2/24/2011($0.19)($0.39)ViewN/AView Earnings Details
10/28/2010Q3 2010($0.20)($0.19)ViewN/AView Earnings Details
7/29/2010Q2 2010($0.19)($0.18)ViewN/AView Earnings Details
4/28/2010Q1 2010($0.20)($0.18)ViewN/AView Earnings Details
2/25/2010Q4 2009($0.17)($0.20)ViewN/AView Earnings Details
10/29/2009Q3 2009($0.21)($0.17)ViewN/AView Earnings Details
7/30/2009Q2 2009($0.19)($0.23)ViewN/AView Earnings Details
4/29/2009Q1 2009($0.20)($0.20)ViewN/AView Earnings Details
2/26/2009Q4 2008($0.21)($0.22)ViewN/AView Earnings Details
10/30/2008Q3 2008($0.20)($0.22)ViewN/AView Earnings Details
7/30/2008Q2 2008($0.20)($0.17)ViewN/AView Earnings Details
4/29/2008Q1 2008($0.18)($0.18)ViewN/AView Earnings Details
2/27/2008Q4 2007($0.12)($0.22)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Geron (NASDAQ:GERN) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Geron (NASDAQ GERN) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 8.20%
Institutional Ownership Percentage: 34.46%
Insider Trading History for Geron (NASDAQ:GERN)
Institutional Ownership by Quarter for Geron (NASDAQ:GERN)

Geron (NASDAQ GERN) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/29/2015Olivia Kyusuk BloomCFOSell2,380$3.84$9,139.20View SEC Filing  
3/18/2015Thomas HofstaetterDirectorSell70,000$4.10$287,000.00View SEC Filing  
5/29/2014Melissa Kelly BehrsEVPSell4,826$2.10$10,134.60View SEC Filing  
5/29/2014Olivia Kyusuk BloomCFOSell3,379$2.10$7,095.90View SEC Filing  
5/9/2014Daniel BradburyDirectorBuy142,776$1.75$249,858.00142,776View SEC Filing  
4/1/2014Melissa Kelly BehrsEVPSell12,310$2.13$26,220.30147,841View SEC Filing  
4/1/2014Olivia Kyusuk BloomCFOSell7,435$2.13$15,836.5585,347View SEC Filing  
4/1/2013John A ScarlettCEOBuy50,000$1.03$51,500.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Geron (NASDAQ GERN) News Headlines

Source:
DateHeadline
Geron Co. (GERN) Receives Average Rating of "Hold" from BrokeragesGeron Co. (GERN) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - May 21 at 1:36 AM
BRIEF-Geron Entered Into Market Issuance Agreement With B. Riley FBRBRIEF-Geron Entered Into Market Issuance Agreement With B. Riley FBR
www.reuters.com - May 18 at 6:00 PM
Making The Bull Case For Geron: Understanding The Risk/Reward Of Telomerase BiologyMaking The Bull Case For Geron: Understanding The Risk/Reward Of Telomerase Biology
seekingalpha.com - May 18 at 6:00 PM
Geron Corp (GERN) Announces Oral Presentation at EHAGeron Corp (GERN) Announces Oral Presentation at EHA
www.streetinsider.com - May 17 at 6:40 PM
Implied Volatility Surging for Geron (GERN) Stock OptionsImplied Volatility Surging for Geron (GERN) Stock Options
finance.yahoo.com - May 16 at 5:41 PM
A Huge Decision Is on Tap for This Little Biotech StockA Huge Decision Is on Tap for This Little Biotech Stock
finance.yahoo.com - May 16 at 5:41 PM
BidaskClub Downgrades Geron (GERN) to SellBidaskClub Downgrades Geron (GERN) to Sell
www.americanbankingnews.com - May 16 at 11:05 AM
Geron Annual Meeting Of Stockholders At 7:00 PM ETGeron Annual Meeting Of Stockholders At 7:00 PM ET
www.nasdaq.com - May 15 at 5:49 PM
Is Geron (GERN) Outperforming Other Medical Stocks This Year?Is Geron (GERN) Outperforming Other Medical Stocks This Year?
finance.yahoo.com - May 14 at 5:20 PM
MARKETS: Don't buy the dip, sell the rip, warns Bank of America Merrill LynchMARKETS: Don't buy the dip, sell the rip, warns Bank of America Merrill Lynch
finance.yahoo.com - May 13 at 6:35 PM
Geron (GERN) Rating Lowered to Hold at ValuEngineGeron (GERN) Rating Lowered to Hold at ValuEngine
www.americanbankingnews.com - May 11 at 9:23 PM
Geron (GERN) Issues Quarterly  Earnings Results, Beats Expectations By $0.01 EPSGeron (GERN) Issues Quarterly Earnings Results, Beats Expectations By $0.01 EPS
www.americanbankingnews.com - May 11 at 2:19 PM
Geron down 8% premarket after Q1 reportGeron down 8% premarket after Q1 report
seekingalpha.com - May 11 at 8:28 AM
Geron: 1Q Earnings SnapshotGeron: 1Q Earnings Snapshot
finance.yahoo.com - May 11 at 8:27 AM
Geron Co. (GERN) Sees Large Growth in Short InterestGeron Co. (GERN) Sees Large Growth in Short Interest
www.americanbankingnews.com - May 11 at 3:06 AM
Geron Corporation Reports First Quarter 2018 Financial ResultsGeron Corporation Reports First Quarter 2018 Financial Results
finance.yahoo.com - May 10 at 5:56 PM
NYSE trader: Earnings and econ data misses this week don't concern meNYSE trader: Earnings and econ data misses this week don't concern me
finance.yahoo.com - May 6 at 7:41 PM
Why Geron Corporation Stock Sank Last MonthWhy Geron Corporation Stock Sank Last Month
www.fool.com - May 4 at 1:17 PM
Geron (GERN) Rating Increased to Buy at ValuEngineGeron (GERN) Rating Increased to Buy at ValuEngine
www.americanbankingnews.com - May 4 at 12:54 AM
Its Illogical To Think That Johnson & Johnson Has Dropped GeronIt's Illogical To Think That Johnson & Johnson Has Dropped Geron
seekingalpha.com - May 1 at 5:18 PM
Geron Bear V. Bull - 50¢ Or $50Geron Bear V. Bull - 50¢ Or $50
seekingalpha.com - May 1 at 8:26 AM
 Analysts Anticipate Geron Co. (GERN) to Post -$0.04 Earnings Per Share Analysts Anticipate Geron Co. (GERN) to Post -$0.04 Earnings Per Share
www.americanbankingnews.com - April 29 at 1:18 AM
Your Daily Pharma Scoop: Geron Debates, Flexion Moves Up, Axsome Proceeds To TrialYour Daily Pharma Scoop: Geron Debates, Flexion Moves Up, Axsome Proceeds To Trial
seekingalpha.com - April 27 at 8:30 AM
Short Interest in Geron Co. (GERN) Decreases By 20.7%Short Interest in Geron Co. (GERN) Decreases By 20.7%
www.americanbankingnews.com - April 27 at 2:58 AM
We Believe Janssen Has Separated From Geron. Just Awaiting Divorce PapersWe Believe Janssen Has Separated From Geron. Just Awaiting Divorce Papers
seekingalpha.com - April 26 at 5:17 PM
Geron Co. (GERN) Receives Consensus Recommendation of "Hold" from BrokeragesGeron Co. (GERN) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - April 26 at 1:42 AM
Is Geron Corporation (GERN) Stock Outpacing Its Medical Peers This Year?Is Geron Corporation (GERN) Stock Outpacing Its Medical Peers This Year?
finance.yahoo.com - April 25 at 5:29 PM
Why Geron Corporation’s (NASDAQ:GERN) Ownership Structure Is ImportantWhy Geron Corporation’s (NASDAQ:GERN) Ownership Structure Is Important
finance.yahoo.com - April 25 at 5:29 PM
Geron (GERN) Lifted to "Buy" at Zacks Investment ResearchGeron (GERN) Lifted to "Buy" at Zacks Investment Research
www.americanbankingnews.com - April 24 at 12:46 PM
Geron (GERN) Stock Rating Lowered by BidaskClubGeron (GERN) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - April 21 at 7:06 AM
Geron (GERN) Given "Buy" Rating at FBR & CoGeron (GERN) Given "Buy" Rating at FBR & Co
www.americanbankingnews.com - April 19 at 10:12 PM
Johnson & Johnson Reaffirms Gerons Imetelstat As Lead Oncology Pipeline DrugJohnson & Johnson Reaffirms Geron's Imetelstat As Lead Oncology Pipeline Drug
seekingalpha.com - April 19 at 5:40 PM
Geron (GERN) Downgraded to Hold at Zacks Investment ResearchGeron (GERN) Downgraded to Hold at Zacks Investment Research
www.americanbankingnews.com - April 19 at 12:49 PM
Geron (GERN) Rating Increased to Buy at Zacks Investment ResearchGeron (GERN) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - April 18 at 12:50 PM
Why Geron Corporations Stock Is Heading Higher TodayWhy Geron Corporation's Stock Is Heading Higher Today
www.fool.com - April 18 at 8:16 AM
Geron Faces A Make-Or-Break Catalyst This WeekGeron Faces A Make-Or-Break Catalyst This Week
seekingalpha.com - April 17 at 5:54 PM
Why Geron Corporation's Stock Is Heading Higher TodayWhy Geron Corporation's Stock Is Heading Higher Today
finance.yahoo.com - April 17 at 5:54 PM
Why Geron Doesnt Pass Our ScreensWhy Geron Doesn't Pass Our Screens
seekingalpha.com - April 16 at 8:16 AM
Why Is Geron (GERN) Up 10.6% Since Its Last Earnings Report?Why Is Geron (GERN) Up 10.6% Since Its Last Earnings Report?
finance.yahoo.com - April 16 at 8:16 AM
Here's Why Geron Stock Surged More Than 90% in 6 MonthsHere's Why Geron Stock Surged More Than 90% in 6 Months
finance.yahoo.com - April 13 at 5:32 PM
Rounds Report: Geron Rallied While FDAs New Guidance Created Tailwinds For Individualized Medicine InnovatorsRounds Report: Geron Rallied While FDA's New Guidance Created Tailwinds For Individualized Medicine Innovators
seekingalpha.com - April 13 at 8:19 AM
Today’s Research Reports on Stocks to Watch: Geron Corp. and Rigel PharmaceuticalsToday’s Research Reports on Stocks to Watch: Geron Corp. and Rigel Pharmaceuticals
finance.yahoo.com - April 13 at 8:19 AM
Why Geron Corporation Stock Is on the Rise TodayWhy Geron Corporation Stock Is on the Rise Today
finance.yahoo.com - April 12 at 3:21 PM
Geron Co. (GERN) Short Interest UpdateGeron Co. (GERN) Short Interest Update
www.americanbankingnews.com - April 12 at 2:18 AM
 Brokerages Anticipate Geron Co. (GERN) to Announce -$0.04 EPS Brokerages Anticipate Geron Co. (GERN) to Announce -$0.04 EPS
www.americanbankingnews.com - April 12 at 1:13 AM
BioSci Rounds Report: Regenxbio Surged, Geron Trading Reversed And Dexcom G6 ApprovedBioSci Rounds Report: Regenxbio Surged, Geron Trading Reversed And Dexcom G6 Approved
seekingalpha.com - April 10 at 8:27 AM
Geron Corp.: Its Hard Enough To Get A Drug To Market Without The Questionable Bearish ArgumentsGeron Corp.: It's Hard Enough To Get A Drug To Market Without The Questionable Bearish Arguments
seekingalpha.com - April 10 at 8:27 AM
Geron Corp.: Its Hard Enough To Get A Drug To Market Without The Misinformed AttacksGeron Corp.: It's Hard Enough To Get A Drug To Market Without The Misinformed Attacks
seekingalpha.com - April 9 at 5:21 PM
Geron (GERN) Downgraded by Zacks Investment ResearchGeron (GERN) Downgraded by Zacks Investment Research
www.americanbankingnews.com - April 7 at 4:58 PM
BioSci Rounds Report: Intercept Making A Comeback, Improving FDA Policy Can Help GeronBioSci Rounds Report: Intercept Making A Comeback, Improving FDA Policy Can Help Geron
seekingalpha.com - April 6 at 5:41 PM

SEC Filings

Geron (NASDAQ:GERN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Geron (NASDAQ:GERN) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Geron (NASDAQ GERN) Stock Chart for Tuesday, May, 22, 2018

Loading chart…

This page was last updated on 5/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.